Patents by Inventor Brendan Lee

Brendan Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12365725
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: July 22, 2025
    Assignees: Genzyme Corporation, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Publication number: 20250190607
    Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for secure communications in a digital engineering ecosystem. In some implementations, a digital platform receives a request from a user device to interact with a digital model. The digital platform determines whether a user operating the user device is authorized. In response to determining the user is authorized to access the digital platform, the digital platform generates a token that provides the user with access to the digital platform. The digital platform determines whether the request includes malicious activity. In response to determining that the request is absent of the malicious activity, the digital platform executes a digital thread that executes one or more operations using digital tools and the digital model. The digital platform provides data indicative of the one or more operations executing the digital thread to the user device.
    Type: Application
    Filed: February 11, 2025
    Publication date: June 12, 2025
    Inventors: William Roper, Jr., Christopher Lee Benson, Sriram Krishnan, Omar Valverde, Ellie Marie Daw, Mohammad Zahra, James C. Pavur, Danne Stayskal Huffaker, Brendan Lee
  • Patent number: 12259995
    Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for secure communications in a digital engineering ecosystem. In some implementations, a digital platform receives a request from a user device to interact with a digital model. The digital platform determines whether a user operating the user device is authorized. In response to determining the user is authorized to access the digital platform, the digital platform generates a token that provides the user with access to the digital platform. The digital platform determines whether the request includes malicious activity. In response to determining that the request is absent of the malicious activity, the digital platform executes a digital thread that executes one or more operations using digital tools and the digital model. The digital platform provides data indicative of the one or more operations executing the digital thread to the user device.
    Type: Grant
    Filed: August 2, 2024
    Date of Patent: March 25, 2025
    Assignee: Istari Digital, Inc.
    Inventors: William Roper, Jr., Christopher Lee Benson, Sriram Krishnan, Omar Valverde, Ellie Marie Daw, Mohammad Zahra, James C. Pavur, Danne Stayskal Huffaker, Brendan Lee
  • Publication number: 20250045441
    Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for secure communications in a digital engineering ecosystem. In some implementations, a digital platform receives a request from a user device to interact with a digital model. The digital platform determines whether a user operating the user device is authorized. In response to determining the user is authorized to access the digital platform, the digital platform generates a token that provides the user with access to the digital platform. The digital platform determines whether the request includes malicious activity. In response to determining that the request is absent of the malicious activity, the digital platform executes a digital thread that executes one or more operations using digital tools and the digital model. The digital platform provides data indicative of the one or more operations executing the digital thread to the user device.
    Type: Application
    Filed: August 2, 2024
    Publication date: February 6, 2025
    Inventors: William Roper, JR., Christopher Lee Benson, Sriram Krishnan, Omar Valverde, Ellie Marie Daw, Mohammad Zahra, James C. Pavur, Danne Stayskal Huffaker, Brendan Lee
  • Publication number: 20240238415
    Abstract: The present disclosure provides methods for treating and improving moderate-to-severe osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of an agent that binds and neutralizes transforming growth factor beta (TGF?).
    Type: Application
    Filed: May 4, 2022
    Publication date: July 18, 2024
    Applicant: Baylor College of Medicine
    Inventor: Brendan LEE
  • Publication number: 20240238230
    Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.
    Type: Application
    Filed: September 8, 2023
    Publication date: July 18, 2024
    Inventor: Brendan Lee
  • Patent number: 12021844
    Abstract: The present invention is a computer-implemented method comprising: identifying, by one or more processors, an image of a user; generating, by the one or more processors, an altered image of the user; receiving, by the one or more processors, confirmation that the user has joined a game, and identifying the relationship between the user and the other participants in the game; altering, by the one or more processors, the other participants user interface where the user is shown with the altered image based on a known relationship with the user; and concealing, by the one or more processors, the user's identity from the participants which do not have a relationship with the user.
    Type: Grant
    Filed: April 24, 2022
    Date of Patent: June 25, 2024
    Inventor: Brendan Lee Courtwright
  • Publication number: 20240102049
    Abstract: The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention for use in the prevention and/or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or Joint disease.
    Type: Application
    Filed: July 14, 2023
    Publication date: March 28, 2024
    Inventors: Merry RUAN, Kilian GUSE, Brendan LEE
  • Publication number: 20240094683
    Abstract: The techniques disclosed herein mitigate stochasticity when controlling a mechanical system with artificial intelligence (AI) agents. In some configurations, AI agents are created using data generated by a machine learning model. Stochasticity is segmented temporally into near term and long term, and different strategies are used to address stochasticity in the different timeframes. For example, long term stochasticity may be addressed with changes to the reward function used to train the model. Short term stochasticity may be addressed by applying a margin to the output of an AI agent. Example margins include window averaging, clamps, and statistical process control bounds. In one configuration, AI agents are regression brains that are generated from setpoints inferred by the model from environmental states. The limitations inherent to fitting a regression line to this data may result in some predicted setpoints being outside of an allowed range.
    Type: Application
    Filed: September 19, 2022
    Publication date: March 21, 2024
    Inventors: Kingsuk MAITRA, Brendan Lee BRYANT, Chris Allen PREMOE, Kence ANDERSON
  • Publication number: 20240093900
    Abstract: The techniques disclosed herein enable utilizing a full range of setpoint values to control a mechanical system. A machine learning model is trained with states collected from the mechanical system. Some of the states may have little to no variation, limiting exploration of possible setpoint values when training the model. To enable a more thorough exploration of possible setpoint values, the states are augmented with a fluctuating delta value that is derived from a fixed setpoint value. For example, a delta outside air temperature may be computed by subtracting outside air temperature, which fluctuates, from a fixed chilled water setpoint. A method of moments computation converts delta values inferred by the model back into absolute values. The absolute values are used to compute a regression equation that is usable by the mechanical system to compute a setpoint action for a given set of input states.
    Type: Application
    Filed: September 19, 2022
    Publication date: March 21, 2024
    Inventors: Kingsuk MAITRA, Brendan Lee BRYANT, Kence ANDERSON
  • Publication number: 20230381267
    Abstract: Embodiments of the present disclosure concern the treatment and/or prevention of Ehlers-Danlos Syndrome (EDS) or its manifestations using therapeutic compositions, such as oxytocin and/or oxytocin analogues. The therapeutic compositions may decrease symptoms and/or reverse disease progression.
    Type: Application
    Filed: September 29, 2021
    Publication date: November 30, 2023
    Inventor: Brendan Lee
  • Publication number: 20230344803
    Abstract: The present invention is a computer- implemented method comprising: identifying, by one or more processors, an image of a user; generating, by the one or more processors, an altered image of the user; receiving, by the one or more processors, confirmation that the user has joined a game, and identifying the relationship between the user and the other participants in the game; altering, by the one or more processors, the other participants user interface where the user is shown with the altered image based on a known relationship with the user; and concealing, by the one or more processors, the user’s identity from the participants which do not have a relationship with the user.
    Type: Application
    Filed: April 24, 2022
    Publication date: October 26, 2023
    Inventor: Brendan Lee Courtwright
  • Patent number: 11786494
    Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: October 17, 2023
    Assignee: Baylor College of Medicine
    Inventor: Brendan Lee
  • Patent number: 11746359
    Abstract: The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention for use in the prevention and/or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or joint disease.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: September 5, 2023
    Assignee: Baylor College of Medicine
    Inventors: Merry Ruan, Kilian Guse, Brendan Lee
  • Patent number: 11699203
    Abstract: Systems and methods for digital property authentication and management are disclosed. A document representing a trade secret may be requested to be registered with a trade secret registry. A document obfuscation value corresponding to the document may be generated and may be registered with a blockchain. A record of the registration may be generated for the trade secret registry. The registry may be searchable and/or offer functionality such as valuation, insurance provision, and/or verification, among other benefits and functionalities.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: July 11, 2023
    Assignee: AON RISK SERVICES, INC. OF MARYLAND
    Inventors: Lewis C. Lee, Daniel Crouse, David Craig Andrews, Samuel Cameron Fleming, Samuel John Desmond, Lewis Brendan Lee
  • Publication number: 20230214792
    Abstract: The invention resides in a blockchain-implemented method of operating a system having a device, the method comprising: using, processing and/or generating a blockchain transaction (MTx) having: one or more token-related outputs (T-UTXO), each of which represents a respective token (T) issued by a Token Issuer (TI) and specifies a) at least one of the operation, status and data that determines the configuration of the device; b) a quantity of token-related cryptocurrency (TRC) associated with the respective token (T). The operation, status and data that determines the configuration and/or status of the device can be determined from instructions on the output of a respective token's blockchain transaction. Generally, assets or resources can be tracked and/or managed using one or more blockchain transactions in which token-related outputs, representing tokens, function to determine the status of an asset.
    Type: Application
    Filed: June 8, 2021
    Publication date: July 6, 2023
    Inventor: Brendan LEE
  • Publication number: 20220348963
    Abstract: The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-I receptor antagonist (IL-1 Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-I receptor antagonist (IL-I Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-I receptor antagonist (IL-I Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 3, 2022
    Inventors: Brendan Lee, Kilian Guse, Zhechao Ruan
  • Publication number: 20220282280
    Abstract: The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention fo ruse in the prevention and/or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or joint disease.
    Type: Application
    Filed: April 1, 2022
    Publication date: September 8, 2022
    Inventors: Merry Ruan, Kilian Guse, Brendan Lee
  • Publication number: 20220195025
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicants: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Patent number: D1044257
    Type: Grant
    Filed: October 18, 2022
    Date of Patent: October 1, 2024
    Assignee: Boa Technology Inc.
    Inventors: Tyler Ziebelman, Brendan Lee